117 related articles for article (PubMed ID: 29019414)
1. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P
Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414
[TBL] [Abstract][Full Text] [Related]
2. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
[TBL] [Abstract][Full Text] [Related]
3. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
[TBL] [Abstract][Full Text] [Related]
4. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
[TBL] [Abstract][Full Text] [Related]
5. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
6. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
Lee DD; Komosa M; Sudhaman S; Leão R; Zhang CH; Apolonio JD; Hermanns T; Wild PJ; Klocker H; Nassiri F; Zadeh G; Diplas BH; Yan H; Gallinger S; Pugh TJ; Ramaswamy V; Taylor MD; Castelo-Branco P; Nunes NM; Tabori U
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720085
[TBL] [Abstract][Full Text] [Related]
7. THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.
Apolónio JD; Dias JS; Fernandes MT; Komosa M; Lipman T; Zhang CH; Leão R; Lee D; Nunes NM; Maia AT; Morera JL; Vicioso L; Tabori U; Castelo-Branco P
Clin Epigenetics; 2022 Dec; 14(1):178. PubMed ID: 36529814
[TBL] [Abstract][Full Text] [Related]
8. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
12. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
13. Exploring hTERT promoter methylation in cutaneous T-cell lymphomas.
Chebly A; Ropio J; Peloponese JM; Poglio S; Prochazkova-Carlotti M; Cherrier F; Ferrer J; Idrissi Y; Segal-Bendirdjian E; Chouery E; Farra C; Pham-Ledard A; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Mol Oncol; 2022 May; 16(9):1931-1946. PubMed ID: 33715271
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging.
Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Pedersen IS; Krarup H; Thorlacius-Ussing O
Int J Cancer; 2017 Dec; 141(12):2489-2497. PubMed ID: 28857158
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer.
Zhao G; Qin Q; Zhang J; Liu Y; Deng S; Liu L; Wang B; Tian K; Wang C
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S301-11. PubMed ID: 22552606
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
[TBL] [Abstract][Full Text] [Related]
18. Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer.
Kumari A; Srinivasan R; Vasishta RK; Wig JD
Ann Surg Oncol; 2009 Apr; 16(4):1051-9. PubMed ID: 19194757
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer.
Zhuang H; Zhou Z; Ma Z; Li Z; Liu C; Huang S; Zhang C; Hou B
J Cell Mol Med; 2020 Nov; 24(22):13481-13493. PubMed ID: 33073486
[TBL] [Abstract][Full Text] [Related]
20. The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC).
Li JJ; Zheng PCJ; Wang YZ
World J Surg Oncol; 2017 Jun; 15(1):114. PubMed ID: 28587656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
